Introduce Satralizum-mwge in Subcu, Perc, New Tech 7

This code describes the administration of Satralizumab-mwge, a monoclonal antibody, directly into the subcutaneous tissue. This procedure is performed percutaneously, meaning through the skin, and is categorized under a specific new technology group.

This code is used for the subcutaneous injection of Satralizumab-mwge for the treatment of neuromyelitis optica spectrum disorder (NMOSD). It applies when the medication is administered by a healthcare professional in an inpatient setting.

• Ensure documentation clearly specifies Satralizumab-mwge as the substance introduced.
• Verify the administration route is subcutaneous and performed percutaneously.